Anika Therapeutics Inc. (AKP)
XBER 
Summary
AKP Chart
Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript
Anika Therapeutics, Inc. ( ANIK ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Matt Hall Cheryl Blanchard - President, CEO & Director Stephen Griffin - Executive VP, CFO & COO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Anika's third quarter earnings conference call. [Operator Instructions] I will now turn the call over to Matt Hall, Director, Corporate Development and Investor Relations.
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.25 per share a year ago.
Anika (ANIK) Upgraded to Buy: Here's What You Should Know
Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anika Therapeutics Inc. (AKP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Anika Therapeutics Inc. ever had a stock split?
Anika Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Cheryl Renee Blanchard CEO | XBER Exchange | US0352551081 ISIN |
| US Country | 288 Employees | - Last Dividend | - Last Split | 29 Apr 1993 IPO Date |
Overview
Anika Therapeutics, Inc. is recognized as a key player in the field of joint preservation, focusing its efforts on the early intervention in orthopedic care. The company's mission revolves around providing innovative solutions for osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions, serving a global market that includes the United States, Europe, and other international regions. The foundation of Anika Therapeutics' product development and commercialization strategies is its proprietary hyaluronic acid (HA) technology platform. The company was established in 1983 and has its headquarters located in Bedford, Massachusetts.
Products and Services
-
OA Pain Management Products
- Monovisc and Orthovisc: These are injectable HA-based viscosupplements designed to alleviate pain from osteoarthritis conditions, providing patients with a non-surgical treatment option.
- Cingal: A cutting-edge, single-injection OA pain management product combining HA with a corticosteroid to offer both immediate and sustained pain relief.
-
Joint Preservation and Restoration
- Hyalofast: A biodegradable support matrix used in the repair and regeneration of cartilage defects, employing the patient's own cells.
- Tactoset: An injectable bone substitute designed to heal bone defects and support bone regeneration, offering a unique solution for orthopedic regenerative needs.
- Sports Medicine Solutions: Includes a range of products used to repair and reconstruct damaged ligaments and tendons, facilitating the recovery of athletes and physically active individuals.
- Partial Joint Replacement and Joint Resurfacing Solutions: These solutions focus on preserving the joints by replacing or resurfacing only the damaged parts, thus maintaining as much of the natural joint structure as possible. They are designed for both upper and lower extremity conditions and aim to offer an alternative to more invasive procedures.
-
Non-Orthopedic Products
- Hyvisc: A high molecular weight injectable HA veterinary product designed for the treatment of joint dysfunction in horses.
- Hyalobarrier: An anti-adhesion gel indicated for use after abdominal-pelvic surgeries to prevent post-surgical adhesions.
- Hyalomatrix: A dermal matrix used to treat burns and ulcers, fostering an environment conducive to the healing of skin wounds.
- In addition, the company offers HA-based products for the treatment of ears, nose, and throat disorders, as well as ophthalmic products, further demonstrating the versatility of its HA technology in addressing a wide range of medical conditions.
Contact Information
